Psychiatry and Neurology, Neurology · Minneapolis, MN
NPI
1821529686
Since 2017
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
913 E 26th St Ste 304
Minneapolis, MN, 55404
Phone (612) 863-3200
Groups this clinician bills Medicare through
Medicare paid, 2024
$221K
34,865 services
Medicare patients, 2024
400
Average age 72
Drug cost, 2024
$1.0M
2,994 prescriptions
Company payments, 2025
$1,185
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David M Kopel was code J0585 (injection, onabotulinumtoxina, 1 unit), 34,000 times for 67 patients. In total David M Kopel billed 34,865 services in 30 codes, and Medicare paid $221K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 34,000 | 67 | $4.48 | $152K |
| 99214 Office E&M - Established | Office | 249 | 186 | $83.71 | $21K |
| 64615 Musculoskeletal | Office | 169 | 66 | $104.55 | $18K |
| 99215 Office E&M - Established | Office | 85 | 74 | $115.26 | $9,797 |
| 99204 Office E&M - New | Office | 79 | 79 | $120.12 | $9,490 |
| 36415 Venipuncture Blood Collection | Office | 63 | 56 | $8.09 | $510 |
| 99213 Office E&M - Established | Office | 44 | 41 | $58.19 | $2,560 |
| 99205 Office E&M - New | Office | 31 | 31 | $156.65 | $4,856 |
| 64405 Musculoskeletal | Office | 18 | 14 | $71.44 | $1,286 |
| 64450 Musculoskeletal | Office | 16 | 13 | $36.20 | $579 |
By year: 2022 $33K for 3,665 services; 2023 $149K for 18,755 services; 2024 $221K for 34,865 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 63 | 56 | $8.09 | $510 |
Medicare prescription drug claims, 2024
In 2024, the drug David M Kopel prescribed most often to Medicare patients was Memantine Hcl, with 207 prescriptions and refills. In total David M Kopel wrote 2,994 Medicare prescriptions that cost $1.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Memantine Hcl Generic | 207 | 375 | 57 | $4,871 |
| Gabapentin Generic | 134 | 239 | 38 | $1,849 |
| Emgality Pen Galcanezumab-Gnlm | 115 | 129 | 25 | $95K |
| Rizatriptan Rizatriptan Benzoate | 112 | 121 | 30 | $3,335 |
| Sumatriptan Succinate Generic | 109 | 120 | 23 | $9,201 |
| Donepezil Hcl Generic | 108 | 221 | 30 | $1,768 |
| Ubrelvy Ubrogepant | 83 | 83 | 34 | $96K |
| Pregabalin Generic | 83 | 125 | 22 | $1,445 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 83 | 153 | 21 | $1,593 |
| Nurtec Odt Rimegepant Sulfate | 76 | 77 | 22 | $105K |
| Levetiracetam Generic | 71 | 183 | 26 | $2,573 |
| Sumatriptan Generic | 63 | 63 | 14 | $17K |
| Aimovig Autoinjector Erenumab-Aooe | 61 | 61 | Under 11 | $45K |
| Duloxetine Hcl Generic | 58 | 86 | 12 | $1,223 |
| Baclofen Generic | 57 | 76 | 23 | $755 |
Brand drugs: 685 claims; generic drugs: 2,298 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David M Kopel $1,185 ($1,185 in general payments such as food, travel and fees) from 23 companies. The largest payer was Abbvie Inc. with $378.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 18 | $378 |
| Pfizer Inc. PFE | 3 | $95.64 |
| TG Therapeutics, Inc. TGTX | 2 | $66.04 |
| Impel Pharmaceuticals LLC | 3 | $61.34 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $59.69 |
| Eisai Inc. 4523.T | 2 | $56.35 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $52.38 |
| Teva Pharmaceuticals USA, Inc. TEVA | 1 | $48.18 |
| EMD Serono, Inc. MRK.DE | 1 | $38.52 |
| Lilly USA, LLC LLY | 2 | $31.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.